Settings
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E26.13 EPS (ttm)2.31 Insider Own0.08% Shs Outstand1.59B Perf Week-3.33%
Market Cap96.16B Forward P/E13.77 EPS next Y4.38 Insider Trans-0.78% Shs Float1.57B Perf Month-8.30%
Income3.71B PEG1.70 EPS next Q0.86 Inst Own87.50% Short Float1.00% Perf Quarter1.38%
Sales19.62B P/S4.90 EPS this Y-23.10% Inst Trans-2.25% Short Ratio2.13 Perf Half Y17.03%
Book/sh2.91 P/B20.74 EPS next Y32.90% ROA12.90% Target Price70.93 Perf Year28.90%
Cash/sh4.85 P/C12.44 EPS next 5Y15.40% ROE77.90% 52W Range44.49 - 70.23 Perf YTD-7.08%
Dividend1.96 P/FCF45.06 EPS past 5Y0.00% ROI23.20% 52W High-14.07% Beta-
Dividend %3.25% Quick Ratio2.50 Sales past 5Y- Gross Margin76.90% 52W Low35.64% ATR1.85
Employees25000 Current Ratio2.60 Sales Q/Q7.80% Oper. Margin29.00% RSI (14)35.53 Volatility2.90% 2.89%
OptionableYes Debt/Eq3.18 EPS Q/Q-48.30% Profit Margin18.90% Rel Volume2.39 Prev Close63.12
ShortableYes LT Debt/Eq3.11 EarningsJan 30 BMO Payout70.40% Avg Volume7.35M Price60.35
Recom2.30 SMA20-5.66% SMA50-8.08% SMA2005.37% Volume17,576,264 Change-4.39%
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Jan-31-15 12:40AM  [$$] AbbVie Takes Hit After Expectations for Hepatitis C Treatment Disappoint at The Wall Street Journal
Jan-30-15 06:23PM  AbbVie Hepatitis C Drug Predictions Disappoint at The Wall Street Journal
06:00PM  Cramer: These boots were made for investing CNBC
06:00PM  AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan PR Newswire
05:51PM  Friday's Market Recap Yahoo Finance Contributors
04:50PM  Another absolutely wild day on Wall Street Yahoo Finance Contributors
04:37PM  AbbVie Shares Slump as Hepatitis C Projections Disappoint at Bloomberg
04:25PM  Mastercard and Amazon are big market movers AP
02:15PM  Abbvie (ABBV) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
01:24PM  AbbVie expects hep C drug sales to top $3 billion per year Reuters
12:49PM  Gilead Sciences v. AbbVie: Who's Winning the Hepatitis-C War? at Barrons.com
12:07PM  AbbVie reports better-than-expected 4Q on Humira sales AP
10:54AM  Eli Lilly's 4Q Earnings Beat, Revenue Outlook Lowered - Analyst Blog Zacks
10:50AM  AbbVie Q4 Earnings Beat Expectations on Humira Strength - Analyst Blog Zacks
10:10AM  Abbvie Expects $3B In Hepatitis C Drug Sales And 40% Of Insured Customers at Forbes
09:47AM  Q4 Earnings Tally, & What It Means - Ahead of Wall Street Zacks
09:20AM  AbbVie (ABBV) Tops 4Q Earnings Estimates, Affirms View - Tale of the Tape Zacks
09:00AM  AbbVie Inc Earnings Call scheduled for 9:00 am ET today CCBN
08:55AM  Are Humira Sales Enough to Lift AbbVie? at 24/7 Wall St.
08:42AM  Drugmaker AbbVie beats estimates as Humira sales rise Reuters
08:01AM  AbbVie reports 4Q loss AP
07:58AM  AbbVie shares up 2.6% as company beats profit, sales estimates at MarketWatch
07:58AM  ABBVIE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:47AM  AbbVie Reports Fourth-Quarter and Full-Year 2014 Financial Results PR Newswire
07:07AM  Q4 2014 AbbVie Inc Earnings Release - Before Market Open CCBN
Jan-29-15 05:37PM  FDA expands use of Imbruvica to treat rare form of blood cancer Reuters
03:16PM  What to Expect When AbbVie (ABBV) Reports Fourth-Quarter Earnings Tomorrow at TheStreet
02:18PM  Baird Remains Buyers Of Gilead Before Earnings Release Benzinga
11:23AM  Abbott Labs' (ABT) Q4 Earnings Up, Guides Below Estimates - Analyst Blog Zacks
08:36AM  Why AbbVie (ABBV) Might Surprise This Earnings Season - Tale of the Tape Zacks
08:27AM  Roche Misses on Earnings in 2014, Beats on Revenues - Analyst Blog Zacks
Jan-28-15 06:30PM  Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog Zacks
05:50PM  Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog Zacks
03:31PM  AmerisourceBergen's Revenue Growth May Slow Further at Investor's Business Daily
02:38PM  HALFTIME FINAL TRADES 1/28/15 at CNBC
12:58PM  FMHR Final Trade: ABBV, PKI & CSX CNBC
12:00PM  Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog Zacks
Jan-27-15 06:10PM  Can St. Jude Medical (STJ) Keep Earnings Streak Alive? - Analyst Blog Zacks
06:05PM  Will Cardinal Health (CAH) Surprise Earnings This Season? - Analyst Blog Zacks
05:45PM  Will PerkinElmer's (PKI) Earnings Disappoint This Season? - Analyst Blog Zacks
05:15PM  Will AmerisourceBergen (ABC) Earnings Surprise in Q1? - Analyst Blog Zacks
04:45PM  Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog Zacks
03:55PM  Varian Medical (VAR): Will Earnings Disappoint in Q1? - Analyst Blog Zacks
03:45PM  Will Baxter International (BAX) Disappoint Earnings in Q4? - Analyst Blog Zacks
03:20PM  Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog Zacks
01:17PM  AbbVie Hepatitis C Drug Will Be Focus of Profit Report --- Earnings Preview at The Wall Street Journal
12:00PM  Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog Zacks
11:20AM  Will Vertex (VRTX) Surprise with a Lower Loss in Q4? - Analyst Blog Zacks
10:30AM  Can CR Bard (BCR) Keep the Earnings Streak Alive in Q4? - Analyst Blog Zacks
10:19AM  Pfizer Beats on Q4 Earnings, Guides Below Expectations - Analyst Blog Zacks
06:20AM  Medtronic: the tax inversion that got away at Financial Times
Jan-26-15 02:39PM  PBM EnvisionRx chooses Gilead hepatitis C drugs for its formulary Reuters
12:41PM  Momenta Pharmaceuticals Done In by Delay at Barrons.com
11:47AM  Medtronics Strategy Takes Shape After Biggest Inversion Ever at Bloomberg
06:53AM  Regeneron vaults ahead of Amgen in race to market cholesterol drug at Fortune
12:00AM  Want To Control Drug Prices? Reject Price Controls! at Forbes
Jan-24-15 11:58AM  German insurers win discounts on Gilead's Sovaldi Reuters
Jan-23-15 05:40PM  Will Accuray (ARAY) Disappoint Earnings Estimates in Q2? - Analyst Blog Zacks
04:00PM  Sanofi's Cerdelga Cleared in the EU for Gaucher Disease - Analyst Blog Zacks
03:50PM  Will Oncology Products Drive Bristol-Myers (BMY) Earnings? - Analyst Blog Zacks
02:40PM  Will Stryker (SYK) Disappoint this Earnings Season? - Analyst Blog Zacks
11:30AM  Will Pfizer (PFE) Beat Q4 Earnings Despite Generics? - Analyst Blog Zacks
Jan-22-15 09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Gilead and Celgene - Press Releases Zacks
Jan-21-15 04:27PM  Deutsche Bank Comments On Concerns Over Consensus Estimates For AbbVie And Gilead Sciences Benzinga
11:02AM  Biotech Stock Roundup: EU Approvals for AbbVie & Celgene Drugs, CytRx Partial Clinical Hold Lifted - Analyst Blog Zacks
Jan-20-15 06:03PM  Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - Analyst Blog Zacks
03:30PM  Sanofi and Boehringer Ingelheim Ink Strategic Deal - Analyst Blog Zacks
02:10PM  Novo Nordisk's Xultophy to Launch First in Switzerland - Analyst Blog Zacks
01:01PM  AbbVie Innovation Center Opens at the University of Illinois-Urbana Research Park Business Wire
11:55AM  J&J Beats on Q4 Earnings, Revenues Hit by Currency - Analyst Blog Zacks
11:50AM  Will Intuitive Surgical (ISRG) Disappoint Earnings in Q4? - Analyst Blog Zacks
11:40AM  Will Quality Systems (QSII) Surprise Earnings this Quarter? - Analyst Blog Zacks
11:20AM  J&J Earnings Beat But Sales, Guidance Miss at Investor's Business Daily
Jan-19-15 06:35PM  AbbVie Gains EU Approval for Hepatitis C Virus Treatment - Analyst Blog Zacks
06:10PM  Roche to Acquire French Biotechnology Company Trophos - Analyst Blog Zacks
04:30PM  Celgene Up as Otezla Gains EU Approval for Two Indications - Analyst Blog Zacks
11:40AM  Will Pharmaceutical Segment Drive J&J Q4 Earnings Again? - Analyst Blog Zacks
09:40AM  Will Logitech (LOGI) Keep the Earnings Streak Alive in Q3? - Analyst Blog Zacks
08:33AM  Impact Of 'Me-Too' Drugs On Health Care Costs at Forbes
04:39AM  AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir) and EXVIERA® (dasabuvir) Licensed for Use in the UK for the Treatment of Chronic Hepatitis C PR Newswire
Jan-18-15 01:38PM  Gilead and AbbVie take hepatitis C battle to Europe at Financial Times
Jan-16-15 03:43PM  Aetna Sides With Gilead In Hepatitis C Drug Battle at Investor's Business Daily
10:08AM  AbbVie Announces U.S. FDA Approval of DUOPA (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease PR Newswire
09:05AM  JP Morgan Healthcare Conference Becomes A Shopping Mall For Wall Street at Forbes
07:54AM  AbbVies hepatitis C drug gets European approval for sale at MarketWatch
07:44AM  European Regulators Approve AbbVie Hepatitis C Drug at The Wall Street Journal
07:00AM  AbbVie to Host Fourth-Quarter and Full-Year 2014 Earnings Conference Call PR Newswire
02:00AM  European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C PR Newswire
Jan-15-15 11:02AM  Eli Lilly Has 'Turned The Corner,' Upgraded at Investor's Business Daily
Jan-14-15 04:30PM  Moody's Upgrades Eight and Affirms 11 Classes of BACM 2007-3 at Moody's
07:55AM  A New Dawn For Biotech? at Forbes
Jan-13-15 02:32PM  Dont look for pricey hepatitis drugs to come down at MarketWatch
Jan-12-15 02:26PM  Shire Agrees To Acquire NPS Pharmaceuticals at Investor's Business Daily
02:00PM  Prime Covers Both Gilead and AbbVie Liver Drugs as Prices Plunge at Bloomberg
12:36PM  Shire to Buy NPS for $5.2 Billion for Rare-Disease Drugs at Bloomberg
09:15AM  Shire Agrees to Pay $5.2 Billion for NPS Pharmaceuticals at TheStreet
08:00AM  AbbVie Announces U.S. FDA Approval of DUOPA (carbidopa and levodopa) Enteral Suspension for the Treatment of Motor Fluctuations in Patients with Advanced Parkinson's Disease PR Newswire
Jan-11-15 06:22PM  Shire to buy NPS for $5.2 billion at USA TODAY
03:53PM  Shire To Acquire NPS Pharmaceuticals for $5.2 Billion Benzinga
Jan-09-15 05:21PM  Stock Pops & Drops: TCS, YELP, ABBV & SBUX CNBC
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM
HURWICH THOMAS A.VP, ControllerNov 24Sale67.811,500101,71763,211Nov 26 05:00 PM
HURWICH THOMAS A.VP, ControllerNov 06Option Exercise24.0710,000240,73171,448Nov 07 05:57 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 04Sale51.204,799245,706395,403Mar 04 05:13 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 03Sale50.034,143207,284273,585Mar 04 05:18 PM
SALEKI-GERHARDT AZITASVP, OperationsMar 03Sale50.252,443122,76085,828Mar 04 05:17 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 03Sale50.223,948198,259180,068Mar 04 05:12 PM
ALBAN CARLOSEVP, Commercial OperationsMar 03Sale50.092,882144,356205,138Mar 04 05:10 PM
HURWICH THOMAS A.VP, ControllerFeb 18Option Exercise44.939,138410,57061,016Feb 19 05:33 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCFeb 18Option Exercise43.218,928385,779256,224Feb 19 05:35 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 18Sale51.2346523,82283,913Feb 19 05:35 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 10Option Exercise45.061,46666,05865,856Feb 12 04:49 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Sale47.8468732,86664,390Feb 07 05:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 05Sale47.781,46069,76385,470Feb 07 05:08 PM